{"id":"W4225464106","doi":"10.1002/cncr.34180","title":"Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","year":2022,"lang":"en","type":"article","venue":"Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Cilag; University of Texas MD Anderson Cancer Center; Genentech; Ipsen; PharmaMar; European Society for Medical Oncology; Shionogi; Astellas Pharma; Eisai; Halozyme; Mirati Therapeutics; National Institutes of Health; Mylan; Arrowhead Pharmaceuticals; Les Laboratories Pierre Fabre; Incyte; Pfizer; Daiichi Sankyo Europe; National Cancer Institute; LEO Pharma; Intuitive Surgical; Merck KGaA; Taiho Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Celgene; PTC Therapeutics; Exelixis; Sanofi; Amgen; EUSA Pharma; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Sunitinib; Hazard ratio; Nivolumab; Renal cell carcinoma; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; Kidney cancer; Proportional hazards model; Survival analysis; Randomized controlled trial; Cancer; Overall survival; Confidence interval; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005620663,0.0002336269,0.0003425929,0.0001241655,0.0001419852,0.00001300701,0.00007819424,0.00003396037,0.0006554957],"category_scores_gemma":[0.000006058887,0.0001884276,0.00003820109,0.000235706,0.0001291121,0.00008065233,0.0000731205,0.0002883995,0.000003791796],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001061595,"about_ca_system_score_gemma":0.000460044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001267627,"about_ca_topic_score_gemma":0.0002361994,"domain_scores_codex":[0.9984118,0.00006685334,0.0001885037,0.0004311363,0.0005698396,0.0003318424],"domain_scores_gemma":[0.9992722,0.00008638178,0.0001033379,0.0002590831,0.0001070392,0.0001719938],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0429467,0.0006268703,0.9508183,0.000106189,0.000108651,0.0006051062,0.0004876368,0.001222029,0.0001560224,0.00002855161,0.0001150261,0.002778922],"study_design_scores_gemma":[0.06531573,0.004719818,0.9284488,0.0000497165,0.0001450249,0.00001716177,0.0001869829,0.00002233455,0.0006358103,0.000001643724,0.000238026,0.0002189381],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964898,0.000615321,0.00000663129,0.00007851479,0.0001653737,0.0007816341,0.0001752968,0.00002594395,0.001661523],"genre_scores_gemma":[0.9982265,0.00001108671,0.00007335968,0.00006472203,0.00006641598,0.0002693313,0.0007114009,0.00004526563,0.0005319268],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02236949,"threshold_uncertainty_score":0.7683856,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0191062222688187,"score_gpt":0.2543971519995092,"score_spread":0.2352909297306905,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}